biostudies-literatureUnknown13La Sala LA successful vaccination would represent the most efficient means to control the pandemic of Coronavirus Disease-19 (COVID-19) that led to millions of deaths worldwide. Novel mRNA-based vaccines confer protective immunity against SARS-CoV-2, but whether immunity is immediately effective and how long it will remain in recipients are uncertain. We sought to assess the effectiveness of a two-dose regimen since the boosts are often delayed concerning the recommended intervals.<h4>Methods</h4>A longitudinal cohort of healthcare workers (HCW, <i>N</i> = 46; 30.4% men; 69.6% women; mean age 36.05 ± 2.2 years) with no SARS-CoV-2 infection as documented by negative polymerase chain reaction was immunophenotyped in PBMC once a week for 4 weeks from the prime immunization (Pfizer mRNA BNT162b2) and hFrontiers in immunology798813https://www.ebi.ac.uk/biostudies/studies/S-EPMC8882867biostudies-literatureSARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence.PMC8882867Sommese CTrabucchi EMeregalli PAllevi RLa Sala LPalano MTLonghi EGandini SGallazzi MSenesi PLuzi LBruno AfalseSARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence.A successful vaccination would represent the most efficient means to control the pandemic of Coronavirus Disease-19 (COVID-19) that led to millions of deaths worldwide. Novel mRNA-based vaccines confer protective immunity against SARS-CoV-2, but whether immunity is immediately effective and how long it will remain in recipients are uncertain. We sought to assess the effectiveness of a two-dose regimen since the boosts are often delayed concerning the recommended intervals.<h4>Methods</h4>A longitudinal cohort of healthcare workers (HCW, <i>N</i> = 46; 30.4% men; 69.6% women; mean age 36.05 ± 2.2 years) with no SARS-CoV-2 infection as documented by negative polymerase chain reaction was immunophenotyped in PBMC once a week for 4 weeks from the prime immunization (Pfizer mRNA BNT162b2) and h2022-01-01T00:00:00Z20222025-04-04T08:41:19.001Z2025-04-04T08:41:19.001ZS-EPMC88828673523726110.3389/fimmu.2022.798813